{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:12:04Z","timestamp":1753521124145,"version":"3.28.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinthera.2024.07.010","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T19:50:40Z","timestamp":1723837840000},"page":"791-798","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial"],"prefix":"10.1016","volume":"46","author":[{"given":"Thomas","family":"Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Gudeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.07.010_bib0001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy \u2013 clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.sleep.2017.11.1125","article-title":"Comorbidities in a community sample of narcolepsy","volume":"43","author":"Cohen","year":"2018","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.004","article-title":"Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study","volume":"33","author":"Black","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.sleep.2016.12.003","article-title":"Narcolepsy type 1 and type 2 \u2013 a 10-year follow-up: body mass index and comorbidities","volume":"32","author":"Cremaschi","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0005","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrn3837","article-title":"The role of orexin in motivated behaviours","volume":"15","author":"Sakurai","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0007","unstructured":"European Medicines Agency. Xyrem. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xyrem. Accessed October 24, 2023."},{"year":"2023","series-title":"Xyrem\u00ae (sodium oxybate). Full Prescribing Information","key":"10.1016\/j.clinthera.2024.07.010_bib0008"},{"year":"2023","series-title":"Xywav\u2122 (calcium, magnesium, potassium, and sodium oxybate). Full Prescribing Information","key":"10.1016\/j.clinthera.2024.07.010_bib0009"},{"year":"2023","series-title":"Xyrem\u00ae (sodium oxybate oral solution, CIII). Full Prescribing Information","key":"10.1016\/j.clinthera.2024.07.010_bib0010"},{"year":"2023","series-title":"LUMRYZ\u2122 (sodium oxybate for extended-release oral suspension, CIII). Full Prescribing Information","key":"10.1016\/j.clinthera.2024.07.010_bib0011"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0012","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.sleep.2022.09.011","article-title":"Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: phase 1 study in healthy volunteers","volume":"100","author":"Bogan","year":"2022","journal-title":"Sleep Med"},{"year":"2024","series-title":"Data on File","key":"10.1016\/j.clinthera.2024.07.010_bib0013"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0014","unstructured":"Avadel Pharmaceuticals. Avadel Pharmaceuticals announces final FDA approval of LUMRYZ\u2122 (sodium oxybate) for extended-release oral suspension as the first and only once-at-bedtime oxybate for cataplexy or excessive daytime sleepiness in adults with narcolepsy. https:\/\/investors.avadel.com\/news-releases\/news-release-details\/avadel-pharmaceuticals-announces-final-fda-approval-lumryztm. Accessed September 18, 2023."},{"key":"10.1016\/j.clinthera.2024.07.010_bib0015","doi-asserted-by":"crossref","first-page":"zsab200","DOI":"10.1093\/sleep\/zsab200","article-title":"Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy","volume":"45","author":"Kushida","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0016","doi-asserted-by":"crossref","first-page":"e12684","DOI":"10.1111\/jsr.12684","article-title":"Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1","volume":"28","author":"Schinkelshoek","year":"2019","journal-title":"J Sleep Res"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0017","doi-asserted-by":"crossref","first-page":"795","DOI":"10.5665\/sleep.3592","article-title":"Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study","volume":"37","author":"Donjacour","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0018","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.sleep.2008.05.012","article-title":"Weight loss in narcolepsy patients treated with sodium oxybate","volume":"10","author":"Husain","year":"2009","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0019","first-page":"296","article-title":"Serum of narcolepsy type 1 patients does not decrease hypocretin receptor 2 function","volume":"27","author":"Schinkelshoek","year":"2018","journal-title":"J Sleep Res"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0020","unstructured":"US Food and Drug Administration. Guidance for industry developing products for weight management. https:\/\/www.fda.gov\/media\/71252\/download. Accessed June 20, 2022."},{"key":"10.1016\/j.clinthera.2024.07.010_bib0021","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/metabo12111120","article-title":"Body weight and metabolic rate changes in narcolepsy: current knowledge and future directions","volume":"12","author":"Dhafar","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0022","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1212\/WNL.0000000000013128","article-title":"Metabolomics signature of patients with narcolepsy","volume":"98","author":"Dauvilliers","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0023","unstructured":"Centers for Disease Control and Prevention. Adult BMI categories. https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html. Accessed August 9, 2024."},{"key":"10.1016\/j.clinthera.2024.07.010_bib0024","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI119587","article-title":"Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men","volume":"100","author":"Van Cauter","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0025","doi-asserted-by":"crossref","first-page":"E1069","DOI":"10.1152\/ajpendo.00623.2010","article-title":"Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls","volume":"300","author":"Donjacour","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0026","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5664\/jcsm.10912","article-title":"Effect of sodium oxybate on body mass index in pediatric patients with narcolepsy","volume":"20","author":"Dauvilliers","year":"2024","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0027","doi-asserted-by":"crossref","first-page":"e3042","DOI":"10.1002\/dmrr.3042","article-title":"Obesity and diabetes-not only a simple link between two epidemics","volume":"34","author":"Chobot","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0028","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.115.306883","article-title":"Obesity and cardiovascular disease","volume":"118","author":"Ortega","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0029","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ecl.2008.06.004","article-title":"Impact of obesity on cardiovascular disease","volume":"37","author":"Zalesin","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101440","article-title":"Cardiovascular disorders in narcolepsy: review of associations and determinants","volume":"58","author":"Jennum","year":"2021","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0031","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0032","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/jsr.12468","article-title":"Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy","volume":"26","author":"Roth","year":"2017","journal-title":"J Sleep Res"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0033","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40263-022-00904-6","article-title":"Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial","volume":"36","author":"Roth","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0034","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.sleep.2023.12.015","article-title":"Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture","volume":"114","author":"Roth","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0035","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/ene.14888","article-title":"European guideline and expert statements on the management of narcolepsy in adults and children","volume":"28","author":"Bassetti","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2024.07.010_bib0036","unstructured":"US Food and Drug Administration. Clinical superiority findings. https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings. Accessed May 11, 2023."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T02:50:35Z","timestamp":1730343035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0149291824002091"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}